Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples